Vishwas Setia

Plus aucun poste en cours

Fortune : 13 M $ au 30/06/2026

39 ans

35 relations

Consumer Services

Finance

Health Technology

Profil

Vishwas Setia worked as an Investment Banking Summer Associate at Merrill Lynch & Co., Inc. in 2013.
Mr. Setia also worked as Chief Financial Officer at MapLight Therapeutics, Inc. from 2024 to 2026.
Mr. Setia completed an MBA degree at Kellogg School of Management in 2014 and holds an undergraduate degree from Delhi College of Engineering.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
MAPLIGHT THERAPEUTICS, INC. 0,84 %	06/05/2026	356 256 ( 0,84 % )	13 M $	30/06/2026

Anciens postes connus de Vishwas Setia

Sociétés	Poste	Fin
MAPLIGHT THERAPEUTICS, INC.	Directeur Financier/CFO	18/06/2026
Merrill Lynch & Co., Inc. /Old/ Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services	Corporate Officer/Principal	01/08/2013

Voir l'expérience en détail de Vishwas Setia

Formation de Vishwas Setia

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Vishwas Setia

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	4
Merrill Lynch & Co., Inc. /Old/ Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services	Finance
Delhi College of Engineering Delhi College of Engineering Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Kellogg School of Management Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
MapLight Therapeutics, Inc. MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders	Health Technology